Lupin's Ankleshwar plant gets US FDA EIR

Lupin's Ankleshwar facility has received an Establishment Inspection Report (EIR) from the US FDA. The EIR follows a recent regulatory inspection and indicates findings are under review. No observations of significance were reported, signaling possible clearance. This paves way for resuming or expanding US drug shipments.

📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA